Cytek Biosciences (CTKB) investor relations material

Key business highlights

• Recognized as a leader in cell analysis with nearly 4,000 systems placed and 3,000 customers in 76 countries.

• Reported $44.1 million in Q1 2026 revenue and nearly $200 million in 2025, with $262.2 million in cash and marketable securities.

• Revenue is globally diversified: 55% USA, 25% EMEA, 20% APAC/rest of world.

• Revenue split: 60% pharma/biotech/distributors, 40% universities/government research.

• Flow cytometry instruments are essential for research in cancer, infectious, and autoimmune diseases.

Technology and innovation

• Pioneered Full Spectrum technology, enabling detection of up to 40 markers per experiment, tripling productivity.

• Launched Borealis, the first seven-laser flow cytometer, allowing up to 60 markers per cell, with early access in 2026.

• Product portfolio includes Aurora Evo, Aurora cell sorter, Amnis imaging, and Northern Lights systems.

• Aurora Evo2, a fully automated system, was introduced, eliminating manual operation.

• Strategic focus on innovation, cloud solutions, and workflow harmonization.

Market and growth drivers

• Addressable market is $5.1 billion in 2025, projected to reach $9.2 billion by 2032, growing at 8.8% CAGR.

• Four business pillars: instruments (60% of revenue), reagents/services (recurring), bioinformatics (Cytek Cloud), and clinical applications.

• Recurring revenue from reagents and services is about a third of total, growing rapidly and expected to reach 40%, with ~19% year-over-year growth in Q1 2026.

• Installed base is growing at high teens rate, driving predictable recurring revenue and service growth.

• Significant opportunity in replacing 46,000 conventional flow cytometers globally.